Beyond the deal: unlocking sustainable success in pharma M&A

12 February 2025

An Expert View from Nick Petschek, EMEA managing director at global change management firm Kotter International.

Mergers and acquisitions (M&A) are set to dominate the pharmaceutical industry in 2025, bringing both challenges and opportunities for pharma businesses looking to grow. This expected wave of activity is driven by a confluence of factors—looming patent cliffs, the need to accelerate innovation, and an evolving regulatory landscape. While the appeal of scale, efficiencies, and market dominance drives many deals, the reality is that financial success often hinges on what happens after the ink dries.

For pharma companies, the stakes of post-M&A integration are uniquely high — not just because of the long timelines for assets to produce value, but because at times the industry overlooks a fundamental priority: putting Hippocratic values first, and balancing shareholder returns with sustained value for patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical